Table 3.
Subject’s Medication at Baseline
| Medication | Walking (W) only (n=79) | Walking and Behavioural (WB) (n=69) | Self-directed (C) (n=74) |
|---|---|---|---|
| Oral hypoglycaemic agents |
|
|
|
| Total |
2 (3) |
5 (7) |
9 (12) |
| Biguanide Class |
2 (3) |
4 (6) |
9 (12) |
| Sulfonylureas Class |
0 (0) |
0 (0) |
2 (3) |
| Thiazolidinedione |
0 (0) |
2 (3) |
2 (3) |
| Antihypertensive Agents |
|
|
|
| Total |
22 (28) |
15 (22) |
15 (22) |
| Calcium channel blockers |
6(8) |
0(0) |
7(9) |
| Antiotensin-converting enzyme |
3 (4) |
7 (10) |
7 (9) |
| Angiotensin II receptor blockers |
6 (8) |
6 (9) |
3 (4) |
| Beta-blocker |
4 (5) |
3 (4) |
4 (5) |
| Alpha-blocker |
3 (4) |
0 (0) |
0 (0) |
| Diuretic |
5 (6) |
8 (12) |
5 (7) |
| Antiarrhythmic |
1 (1) |
0 (0) |
0 (0) |
| Anti-anginal |
1 (1) |
0 (0) |
0 (0) |
| Anti-platelet agent |
1 (1) |
1 (1) |
1 (1) |
| Anticoagulant |
0 (0) |
2 (3) |
0 (0) |
| Phosphodiesterase type 5 inhibitors |
0 (0) |
1 (1) |
0 (0) |
| Statins |
8 (10) |
12 (17) |
10 (14) |
| Hormone |
|
|
|
| Total |
11 (14) |
10 (14) |
11 (15) |
| Thyroid |
5 (6) |
5 (7) |
8 (11) |
| Insulin |
0 (0) |
3 (4) |
1 (1) |
| Corticosteroid |
4 (5) |
2 (3) |
3 (4) |
| Progesterone |
1 (1) |
0 (0) |
1 (1) |
| Androgen |
1 (1) |
0 (0) |
0 (0) |
| Oestrogen |
1 (1) |
0 (0) |
0 (0) |
| Antithyroid |
0 (0) |
1 (1) |
0(0) |
| SERMs (Selective estrogen receptor modifiers) |
1 (1) |
0 (0) |
0 (0) |
| Beta 2-adrenergic receptor agonist (bronchodilator) |
2(3) |
1 (1) |
3 (4) |
| NSAIDs (Non-steroid anti-inflammatory drugs) |
26 (33) |
21 (30) |
18 (24) |
| COX-2 selective inhibitor |
3 (4) |
4 (6) |
1 (1) |
| NSAIDS |
|
|
|
| Betahistine |
0 (0) |
1 (1) |
0 (0) |
| DMARDs (Disease modifying antirheumatic drugs) |
0 (0) |
1 (1) |
0 (0) |
| Histamine antagonist |
0 (0) |
2 (3) |
0 (0) |
| Bisphosphonate |
6 (8) |
4 (6) |
4 (5) |
| Antibiotics |
2 (3) |
1 (1) |
4 (5) |
| Analgesics |
1 (1) |
1 (1) |
3 (4) |
| Opiates |
0 (0) |
0 (0) |
2 (3) |
| Hypnotic |
4 (5) |
3 (4) |
4 (5) |
| Antidepressant |
7 (9) |
5 (7) |
7 (9) |
| Psychostimulant |
0 (0) |
1 (1) |
0 (0) |
| Antipsychotic |
0 (0) |
1 (1) |
0 (0) |
| Anti-manic |
0 (0) |
1 (1) |
0 (0) |
| Anti-convulsant |
1 (1) |
1 (1) |
0 (0) |
| Protein pump inhibitor (PPI) |
9 (11) |
5 (6) |
6 (8) |
| Enzyme inhibitor |
0 (0) |
1 (1) |
2 (3) |
| Muscle relaxant |
0 (0) |
1 (1) |
1 (1) |
| Antispasmodic |
0 (0) |
1 (1) |
0 (0) |
| Anti-cholinergic |
1 (1) |
1 (1) |
0 (0) |
| Antineoplastic |
2 (3) |
1 (1) |
0 (0) |
| Antimetabolite |
1 (1) |
1 (1) |
1 (1) |
| Antifolate |
0 (0) |
1 (1) |
1 (1) |
| Latanoprost |
0 (0) |
1 (1) |
0 (0) |
| Viscosupplementation |
0 (0) |
1 (1) |
0 (0) |
| Xanthine |
1 (1) |
0 (0) |
0 (0) |
| Antifungals |
0 (0) |
0 (0) |
1 (1) |
| Antimalarial |
0 (0) |
1 (1) |
1 (1) |
| Nitrate |
0 (0) |
0 (0) |
2 (3) |
| Laxative |
0 (0) |
0 (0) |
2 (3) |
| Supplements |
22 (28) |
22 (28) |
18 (24) |
| Homeopathic Medication |
1 (1) |
1 (1) |
1 (1) |
| None |
11 (14) |
10 (13) |
9 (12) |
| Not Specific |
21 (27) |
21 (27) |
20 (27) |
| Missing Data |
|
|
|
| Total |
4 (5) |
8 (10) |
17 (23) |
| No Evaluation* |
2 (3) |
4 (5) |
7 (9) |
| No File** | 2 (3) | 4 (6) | 10 (14) |
This table presents a list of medications which participants declared to be taking at baseline. Data is presented as n (%).